Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects

Berstein, Lev M.; Maximov, S.; Gershfeld, Eduard Dmitriyevich; Meshkova, Irina; Gamajunova, V. B.; Цырлина, Е. В.; Larionov, Alexey; Kovalevskij, A.; Vasilyev, D. A.

doi:10.1016/s0301-2115(02)00147-1

Cited by 50 publications

(31 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3A). Although efficacy is variable based on a few case studies (Rose et al 2000, Berstein et al 2002, Burnett et al 2004, Leunen et al 2004, AIs do show promise as an alternative endocrine therapy for EC especially who has high sensitivity to AI. Our system suggests that AIs may be effective in a subset of carefully screened patients with estrogendependent EC.…”

Section: Discussionmentioning

confidence: 99%

Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction

Matsumoto

Yamaguchi

Seino

et al. 2008

Endocrine Related Cancer

View full text Add to dashboard Cite

The estrogen pathway plays an important role in the etiology of human endometrial carcinoma (EC). We examined whether estrogen biosynthesis in the tumor microenvironment promotes endometrial cancer. To examine the contribution of stromal cells to estrogen signaling in EC, we used reporter cells stably transfected with the estrogen response element (ERE) fused to the destabilized green fluorescent protein (GFP) gene. In this system, the endometrial cancer stromal cells from several patients activated the ERE of cancer cells to a variable extent. The GFP expression level increased when testosterone, a substrate for aromatase, was added. The effect was variably inhibited by aromatase inhibitors (AIs), although the response to AIs varied among patients. These results suggest that GFP expression is driven by estrogen synthesized by aromatase in the endometrial cancer stromal cells. In a second experiment, we constructed an adenovirus reporter vector containing the same construct as the reporter cells described above, and visualized endogenous ERE activity in primary culture cancer cells from 15 EC specimens. The GFP expression levels varied among the cases, and in most primary tissues, ERE activities were strongly inhibited by a pure anti-estrogen, fulvestrant. Interestingly, a minority of primary tissues in endometrial cancer showed ERE activity independent of the estrogen-ER pathway. These results suggest that AI may have some therapeutic value in EC; however, the hormonal microenvironment must be assessed prior to initiating therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction

Matsumoto

Yamaguchi

Seino

et al. 2008

Endocrine Related Cancer

View full text Add to dashboard Cite

show abstract

“…Aromatase inhibitors would be potential agents for endocrine therapy and prevention of endometrial cancer (31). In vitro treatment of endometrial cancer tissues with aromatase inhibitors showed that depletion of in situ estrogen results in decreased cell proliferation of tumor cells (32).…”

Section: Discussionmentioning

confidence: 99%

Aromatase Expression in Stromal Cells of Endometrioid Endometrial Cancer Correlates with Poor Survival

Segawa

Shozu

Murakami

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Currently available third-generation aromatase inhibitors may be used for endocrine treatment of endometrial cancer (Berstein et al, 2002). Treatment of endometrial cancer tissues in vitro with aromatase inhibitors demonstrated that in situ depletion of estrogen results in decreased cell proliferation of tumor cells (Sasano et al, 1999).…”

Section: Aromatase and Endometrial Cancermentioning

confidence: 99%

Regulation of Aromatase Expression in Estrogen-Responsive Breast and Uterine Disease: From Bench to Treatment

Bulun¹,

Lin²,

İmir³

et al. 2005

Pharmacol Rev

468

462

View full text Add to dashboard Cite

Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects

Cited by 50 publications

References 13 publications

Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction

Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction

Aromatase Expression in Stromal Cells of Endometrioid Endometrial Cancer Correlates with Poor Survival

Regulation of Aromatase Expression in Estrogen-Responsive Breast and Uterine Disease: From Bench to Treatment

Contact Info

Product

Resources

About